<?xml version='1.0' encoding='utf-8'?>
<document id="10235417"><sentence text="Pantoprazole lacks induction of CYP1A2 activity in man."><entity charOffset="0-12" id="DDI-PubMed.10235417.s1.e0" text="Pantoprazole" /></sentence><sentence text="This drug-drug interaction study investigated the potential influence of the proton pump inhibitor pantoprazole on the CYP1A2 activity as assessed by urinary excretion of caffeine metabolites"><entity charOffset="99-111" id="DDI-PubMed.10235417.s2.e0" text="pantoprazole" /><entity charOffset="171-179" id="DDI-PubMed.10235417.s2.e1" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.10235417.s2.e0" e2="DDI-PubMed.10235417.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10235417.s2.e0" e2="DDI-PubMed.10235417.s2.e1" /></sentence><sentence text="" /><sentence text="12 healthy, non-smoking volunteers underwent two treatment periods of 7 days each in randomized order with once-daily oral intake of 40 mg pantoprazole (test) or placebo (reference)"><entity charOffset="139-151" id="DDI-PubMed.10235417.s4.e0" text="pantoprazole" /></sentence><sentence text=" On days 6 and 7 of both periods, 200 mg caffeine was administered two hours after pantoprazole intake, i"><entity charOffset="41-49" id="DDI-PubMed.10235417.s5.e0" text="caffeine" /><entity charOffset="83-95" id="DDI-PubMed.10235417.s5.e1" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.10235417.s5.e0" e2="DDI-PubMed.10235417.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10235417.s5.e0" e2="DDI-PubMed.10235417.s5.e1" /></sentence><sentence text="e" /><sentence text=" at the expected t(max) of pantoprazole serum concentrations"><entity charOffset="27-39" id="DDI-PubMed.10235417.s7.e0" text="pantoprazole" /></sentence><sentence text=" Urinary excretion of the caffeine metabolites 1X, 1U, AFMU, 17U was measured up to 8 hours after caffeine intake"><entity charOffset="26-34" id="DDI-PubMed.10235417.s8.e0" text="caffeine" /><entity charOffset="98-106" id="DDI-PubMed.10235417.s8.e1" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.10235417.s8.e0" e2="DDI-PubMed.10235417.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10235417.s8.e0" e2="DDI-PubMed.10235417.s8.e1" /></sentence><sentence text=" In accordance with recent guidelines on drug-drug interactions, lack of interaction was handled as an equivalence problem" /><sentence text="" /><sentence text="Point estimate and 90% confidence intervals (CI) of the respective ratios test/reference were 0" /><sentence text="91 (0" /><sentence text="81, 1" /><sentence text="03) for (1X + 1U + AFMU)/17U, indicative for CYP1A2 activity, 1" /><sentence text="03 (0" /><sentence text="94, 1" /><sentence text="13) for AFMU/1X (N-acetyl transferase activity) and 1" /><sentence text="01 (0" /><sentence text="94, 1" /><sentence text="09) for 1U/1X (xanthine oxidase activity)"><entity charOffset="15-23" id="DDI-PubMed.10235417.s20.e0" text="xanthine" /></sentence><sentence text="" /><sentence text="Pantoprazole does not induce CYP1A2 activity, consistent with previous findings following theophylline administration, nor does it have any influence on N-acetyl-transferase or xanthine oxidase activity"><entity charOffset="0-12" id="DDI-PubMed.10235417.s22.e0" text="Pantoprazole" /><entity charOffset="90-102" id="DDI-PubMed.10235417.s22.e1" text="theophylline" /><entity charOffset="177-185" id="DDI-PubMed.10235417.s22.e2" text="xanthine" /><pair ddi="false" e1="DDI-PubMed.10235417.s22.e0" e2="DDI-PubMed.10235417.s22.e0" /><pair ddi="false" e1="DDI-PubMed.10235417.s22.e0" e2="DDI-PubMed.10235417.s22.e1" /><pair ddi="false" e1="DDI-PubMed.10235417.s22.e0" e2="DDI-PubMed.10235417.s22.e2" /><pair ddi="false" e1="DDI-PubMed.10235417.s22.e1" e2="DDI-PubMed.10235417.s22.e1" /><pair ddi="false" e1="DDI-PubMed.10235417.s22.e1" e2="DDI-PubMed.10235417.s22.e2" /></sentence><sentence text="" /></document>